Contact Us
Phase-Xs | Biologics & Biosimilars | Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Immunomodulators are chemicals that can aid immune function by altering the immune system's response to a threat, usually in a favorable way. Immunomodulators may be used alone or in combination with other drugs  (such as a corticosteroid) to treat nonresponse or intolerance to aminosalicylates, antibiotics, or corticosteroids, to prevent recurrence after surgery, to bolster or optimize the effect of a biologic drug, and to prevent the development of biologic drug resistance, among other things. By product type, they are segmented into immunosuppressants and immunostimulants. Immunosuppressants suppress the immune response in organ transplantation and autoimmune illnesses, whereas immunostimulants boost the immune response in infections, immunodeficiency (such as AIDS), and malignancies.

The global immunomodulators market is estimated to be valued at US$ 91850.0 Million in 2021 and is expected to reach US$ 156378.2 million by 2028, at a CAGR of 7.9% during the forecast period (2021–2028).

Figure 1. Global Immunomodulators Market Share (%), By Region, 2021

Immunomodulators  | Coherent Market Insights

Rising prevalence of multiple sclerosis is expected to drive the market growth over the forecast period.

Multiple sclerosis (MS) is the second leading cause of death, after cardiovascular diseases. Rising prevalence of multiple sclerosis is expected to drive the market growth over the forecast period. For instance, according to a report published in the Multiple Sclerosis Journal 2020, MS affected an estimated 2.8 million people around the world (35.9 per 100,000 population). Since 2013, despite the fact that MS has become more common in every part of the world, there are still disparities in prevalence estimates. The average age of diagnosis is 32 years, and the pooled incidence rate across 75 reporting nations is 2.1 per 100,000 people each year. MS affects twice as many women as it does men.

request-sample

Immunomodulators Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 91850.0 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 7.9% 2028 Value Projection: US$ 156378.2 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product Type: Immunosuppressants (Calcineurin Inhibitors, Glucocorticoids, Antimetabolites, Others), Immunostimulants (Vaccines, Antibodies, Others)
  • By Application: Oncology, Respiratory, HIV, Others
  • By End User: Hospitals, Clinics, Others
Companies covered:

F. Hoffmann-La Roche Ltd., Biogen Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Amgen, Inc., Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., Eli Lilly and Company, Abbott Laboratories, Johnson & Johnson, and Pfizer Inc.

Growth Drivers:
  • Rising prevalence of multiple sclerosis
  • Increasing prevalence of autoimmune disorders
  • Rising availability of drugs
  • Rising number of ongoing clinical trials for the development of immunotherapeutic agents
Restraints & Challenges:
  • Side effects associated with immunomodulating drugs 
  • Strict regulations with respect to clinical studies by regulatory bodies

Figure 2. Global Immunomodulators Market Share, By Application, 2021

Immunomodulators  | Coherent Market Insights

Rising cases of rheumatoid arthritis is expected to boost the market growth.

The number of active clinical trials to develop immunotherapeutic drugs, such as laquinimod, ozanimod, and ponesimod, is expected to drive the global immunomodulators market in the forecast period. Apart from that, the growing need to treat autoimmune diseases such as rheumatoid arthritis is expected to drive demand for immunomodulators. For instance, in 2018, an estimated 400,000 people in the U.K. had rheumatoid arthritis, and an estimated four million people had an autoimmune disease, according to the British Society for Global Immunomodulators.

Global Immunomodulators Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it as a public health emergency in 2020. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the number of COVID-19 cases reported globally as of August 2, 2021, are approximately 198,234,951 confirmed cases with around 4,227,359 deaths. The Coronavirus (COVID-19) outbreak started from Wuhan, China and has spread across continents, affecting various industries globally.

The COVID-19 pandemic is expected to have a favorable impact on the industry in the foreseeable future, owing to increased sales of immunomodulating products. Furthermore, in order to maintain sales, several key players strive to establish a balance between demand and supply. They're also attempting to increase their investments in quality control, refine their R&D efforts, and improve supply chain management.

Global Immunomodulators Market: Restraint

Side effects associated with immunomodulating drugs such as Thalidomide (Thalomid), lenalidomide (Revlimid), and pomalidomide (Pomalyst) include drowsiness, exhaustion, constipation, low blood cell counts, and neuropathy (painful nerve damage). There's also a higher chance of major blood clots formation (that start in the leg and can travel to the lungs). With thalidomide, this is more common than with the other medicines (lenalidomide and pomalidomide). Additionally, strict regulations with respect to clinical studies by regulatory bodies is hampering the market growth.

Key Players

Major players operating in the global immunomodulators market include F. Hoffmann-La Roche Ltd., Biogen Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Amgen, Inc., Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., Eli Lilly and Company, Abbott Laboratories, Johnson & Johnson, and Pfizer Inc.

Immunomodulators are medications that either stimulate or inhibit the immune system. They affect the immunological response by modifying the immune system. Immunomodulators function by lowering the amount of antibodies produced in response to foreign antigens, which stimulate immune reactions. Immunosuppressants and immunostimulants are two different categories of immunomodulators. Corticosteroids, thymosin, and immunoglobulins are a few of the  Immunomodulators. Cancer, infection, asthma, and other disorders are treated with these drugs. Immunosuppressants are commonly used to avoid organ rejection during various transplant procedures. Immunostimulants could possibly be utilized to treat HIV and cancer.

Inflammatory bowel disease (IBD), notably ulcerative colitis (UC), and Crohn's disease (CD), can be effectively treated with  immunomodulators. Immunomodulators are also commonly employed in organ transplants and the treatment of autoimmune illnesses. Steroids are sometimes taken in conjunction with immunomodulators to speed up the effect of immunomodulators. They are used in contemporary vaccination formulations and play an important role in pharmaceuticals. Immunomodulation focuses on manipulating the immune system to reduce infections and other negative health impacts while maintaining precise control to avoid problems such as frequent and recurrent pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, and others. Simultaneously, efforts to improve animal and human health by suppressive or potentiating measures are made.

Market Dynamics

The rising prevalence of autoimmune illnesses such as rheumatoid arthritis, systemic lupus erythematosus (Lupus), juvenile rheumatoid arthritis, inflammatory bowel arthritis, Psoriatic arthritis, and others is a major contributor to the global immunomodulators market's expansion. For instance, according to the National Institutes of Health, up to 23.5 million Americans (almost 7% of the population) had an autoimmune disease in 2017, resulting in a larger patient pool and, in turn, a larger market.

Key features of the study:

  • This report provides in-depth analysis of the immunomodulators market, and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the Global Immunomodulators market based on the following parameters – company highlights, types portfolio, key highlights, financial performance, and market strategies
  • Key companies covered as a part of this study include F. Hoffmann-La Roche Ltd., Biogen Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Amgen, Inc., Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., Eli Lilly and Company, Abbott Laboratories, Johnson & Johnson, and Pfizer Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global immunomodulators market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the immunomodulators market

Detailed Segmentation:

  • Global Immunomodulators Market, By Product Type:
    • Immunosuppressants
      • Calcineurin Inhibitors
      • Glucocorticoids
      • Antimetabolites
      • Others
    • Immunostimulants
      • Vaccines
      • Antibodies
      • Others
  • Global Immunomodulators Market, By Application:
    • Oncology
    • Respiratory
    • HIV
    • Others
  • Global Immunomodulators Market, By End User:
    • Hospitals
    • Clinics
    • Others
  • Global Immunomodulators Market, By Region:
    • North America
      • By Product Type
        • Immunosuppressants
          • Calcineurin Inhibitors
          • Glucocorticoids
          • Antimetabolites
          • Others
        • Immunostimulants
          • Vaccines
          • Antibodies
          • Others
      • By Application
        • Oncology
        • Respiratory
        • HIV
        • Others
      • By End User
        • Hospitals
        • Clinics
        • Others
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Product Type
        • Immunosuppressants
          • Calcineurin Inhibitors
          • Glucocorticoids
          • Antimetabolites
          • Others
        • Immunostimulants
          • Vaccines
          • Antibodies
          • Others
      • By Application
        • Oncology
        • Respiratory
        • HIV
        • Others
      • By End User
        • Hospitals
        • Clinics
        • Others
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Product Type
        • Immunosuppressants
          • Calcineurin Inhibitors
          • Glucocorticoids
          • Antimetabolites
          • Others
        • Immunostimulants
          • Vaccines
          • Antibodies
          • Others
      • By Application
        • Oncology
        • Respiratory
        • HIV
        • Others
      • By End User
        • Hospitals
        • Clinics
        • Others
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Product Type
        • Immunosuppressants
          • Calcineurin Inhibitors
          • Glucocorticoids
          • Antimetabolites
          • Others
        • Immunostimulants
          • Vaccines
          • Antibodies
          • Others
      • By Application
        • Oncology
        • Respiratory
        • HIV
        • Others
      • By End User
        • Hospitals
        • Clinics
        • Others
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Product Type
        • Immunosuppressants
          • Calcineurin Inhibitors
          • Glucocorticoids
          • Antimetabolites
          • Others
        • Immunostimulants
          • Vaccines
          • Antibodies
          • Others
      • By Application
        • Oncology
        • Respiratory
        • HIV
        • Others
      • By End User
        • Hospitals
        • Clinics
        • Others
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Product Type
        • Immunosuppressants
          • Calcineurin Inhibitors
          • Glucocorticoids
          • Antimetabolites
          • Others
        • Immunostimulants
          • Vaccines
          • Antibodies
          • Others
      • By Application
        • Oncology
        • Respiratory
        • HIV
        • Others
      • By End User
        • Hospitals
        • Clinics
        • Others
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Hoffmann-La Roche Ltd.
      • Company Highlights
      • Product Portfolio
      • Key Highlights
      • Financial Performance
      • Market Strategies
    • Biogen Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Novartis AG
    • Amgen, Inc.
    • Bristol-Myers Squibb Company
    • Merck Sharp & Dohme Corp.
    • Eli Lilly and Company
    • Abbott Laboratories
    • Johnson & Johnson
    • Pfizer Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snapshot, By Product Type
      • Market Snapshot, By Application
      • Market Snapshot, By End User
      • Market Snapshot, By Region
      • Market Opportunity Map
  3. Global Immunomodulators Market Insights
    • Drivers
    • Restraints
    • Opportunity
    • Impact Analysis
    • Pipeline Analysis
    • Market Trends
    • New Product Launches
    • Key Developments
    • Regulatory Scenario
    • Advances in R&D for Immunology
    • Collaborations & Acquisitions
    • Epidemiology
    • PEST Analysis
    • Porter’s five forces analysis
  4. Global Immunomodulators Market - Impact of Coronavirus (Covid-19) Pandemic
    • Economic Impact
    • COVID-19 Epidemiology
    • Impact of COVID-19 on demand and supply chain
  5. Global Immunomodulators Market, By Product Type, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Immunosuppressants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
        • Calcineurin Inhibitors
        • Glucocorticoids
        • Antimetabolites
        • Others
    • Immunostimulants
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
        • Vaccines
        • Antibodies
        • Others
  6. Global Immunomodulators Market, By Application, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Oncology
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Respiratory
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • HIV
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
  7. Global Immunomodulators Market, By End User, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028 (US$ Million)
  8. Global Immunomodulators Market, By Region, 2017 – 2028 (US$ Million)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Region at Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2028, (US$ Million)
        • U.S.
        • Canada
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2028, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2028, (US$ Million)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2028, (US$ Million)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country, 2017–2028, (US$ Million)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, By Product Type, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By Application, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast, and Y-o-Y Growth, By End User, 2017 – 2028, (US$ Mn)
      • Market Size and Forecast By Value, and Y-o-Y Growth, By Country/Region, 2017–2028, (US$ Million)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Snapshot
    • Company Profiles
      • Hoffmann-La Roche Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Biogen Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Novartis AG
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Amgen, Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Bristol-Myers Squibb Company
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Merck Sharp & Dohme Corp.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Eli Lilly and Company
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Abbott Laboratories
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Johnson & Johnson
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
      • Pfizer Inc.
        • Company Highlights
        • Product Portfolio
        • Key Highlights
        • Financial Performance
        • Market Strategies
  10. Section
    • Research Methodology
    • About us

*Browse 35 market data tables and 30 figures on "Global Immunomodulators Market” - Global forecast to 2028

FAQgrowicon

Frequently Asked Questions

The global immunomodulators market size is estimated to be valued at US$ 91850.0 Million in 2021 and is expected to exhibit a CAGR of 7.9% between 2021 and 2028.
Rising prevalence of multiple sclerosis, increasing prevalence of autoimmune disorders, rising availability of drugs, and rising number of ongoing clinical trials for the development of immunotherapeutic agents are the major factors driving the growth of market.
The immunosuppressants segment is the leading product type segment in the market.
Side effects associated with immunomodulating drugs and strict regulations with respect to clinical studies by regulatory bodies are the major factors restraining growth of the market.
Major players operating in the market includes F. Hoffmann-La Roche Ltd., Biogen Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Amgen, Inc., Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., Eli Lilly and Company, Abbott Laboratories, Johnson & Johnson, and Pfizer Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly Subscribe for our latest news & articles.